Volume 95 Issue 34 | p. 15 | Concentrates
Issue Date: August 28, 2017

Samsung, Takeda team for new biologics

Department: Business
Keywords: Biologics, Takeda, Samsung, drug development
[+]Enlarge
Samsung Bioepis focuses on innovating expedited drug development processes.
Credit: Samsung Bioepis
Male researcher in the foreground of a bank of computers in a Samsung laboratory, holding a stack of papers with a paper clip as a group of female researcher huddle in the back of the laboratory
 
Samsung Bioepis focuses on innovating expedited drug development processes.
Credit: Samsung Bioepis

Samsung Bioepis and Takeda Pharmaceutical are joining to develop new biologic therapies for areas of unmet medical need. The partners’ first program is TAK-671, a treatment for pancreatitis. Samsung Bioepis launched in 2012 as a manufacturer of the generic biologic drugs known as biosimilars. “Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” says CEO Christopher Hansung Ko.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment